Your browser doesn't support javascript.
loading
The effects of recombinant human insulin-like growth factor-1/insulin-like growth factor binding protein-3 administration on lipid and carbohydrate metabolism in recreational athletes.
Guha, Nishan; Nevitt, Simon P; Francis, Michael; Böhning, Walailuck; Böhning, Dankmar; Sönksen, Peter H; Holt, Richard I G.
Afiliación
  • Guha N; Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Nevitt SP; Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Francis M; Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Böhning W; Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Böhning D; Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Sönksen PH; Southampton Statistical Sciences Research Institute, University of Southampton, Southampton, UK.
  • Holt RIG; Human Development and Health, Faculty of Medicine, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Clin Endocrinol (Oxf) ; 94(4): 551-562, 2021 04.
Article en En | MEDLINE | ID: mdl-33249593
ABSTRACT

OBJECTIVE:

Previous studies suggested that recombinant human IGF-1 (rhIGF-1) administration affects carbohydrate and lipid metabolism in healthy people and in people with diabetes. This study aimed to determine the effects of rhIGF-1/rhIGF binding protein-3 (rhIGFBP-3) administration on glucose homeostasis and lipid metabolism in healthy recreational athletes. DESIGN AND

SETTING:

Randomized, double-blind, placebo-controlled rhIGF-1/rhIGFBP-3 administration study at Southampton General Hospital, UK.

PARTICIPANTS:

56 recreational athletes (30 men, 26 women).

METHODS:

Participants were randomly assigned to receive placebo, low-dose rhIGF-1/rhIGFBP-3 (30 mg/day) or high-dose rhIGF-1/rhIGFBP-3 (60 mg/day) for 28 days. The following variables were measured before and immediately after the treatment period fasting lipids, glucose, insulin, C-peptide and glycated haemoglobin. The homeostatic model assessment (HOMA-IR) was used to estimate insulin sensitivity and indirect calorimetry to assess substrate oxidation rates. The general linear model approach was used to compare treatment group changes with the placebo group.

RESULTS:

Compared with the placebo group, there was a significant reduction in fasting triglycerides in participants treated with high-dose rhIGF-1/rhIGFBP-3 (p = .030), but not in the low-dose group (p = .390). In women, but not in men, there were significant increases in total cholesterol (p = .003), HDL cholesterol (p = .001) and LDL cholesterol (p = .008). These lipid changes were associated with reduced fasting insulin (p = .010), C-peptide (p = .001) and HOMA-IR (p = .018) in women and reduced C-peptide (p = .046) in men.

CONCLUSIONS:

rhIGF-1/rhIGFBP-3 administration for 28 days reduced insulin concentration, improved insulin sensitivity and had significant effects on lipid profile including decreased fasting triglycerides.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor I del Crecimiento Similar a la Insulina / Proteínas Portadoras / Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina / Atletas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Clin Endocrinol (Oxf) Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor I del Crecimiento Similar a la Insulina / Proteínas Portadoras / Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina / Atletas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Clin Endocrinol (Oxf) Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido